Allogene Advances Dual-Target CAR T Strategy in Multiple Myeloma

Allogene Therapeutics has published preclinical data evaluating an allogeneic BCMA/CD70 dual-targeting CAR T cell construct for high-risk multiple myeloma, a disease setting where single-target approaches have faced persistent antigen escape and relapse challenges. For QA and process development teams tracking the allogeneic cell therapy manufacturing space, the dual-antigen architecture signals a meaningful shift in how off-the-shelf CAR T programs are being designed to address tumor heterogeneity at the molecular level.

The construct targets both B-cell maturation antigen (BCMA) and CD70, two antigens with established expression profiles in multiple myeloma. The allogeneic format, central to Allogene's AlloCAR T platform, is intended to enable on-demand availability without the manufacturing delays and patient-specific variability inherent to autologous approaches. For plant heads and process validation leads, this positions the program within the broader industry effort to standardize CAR T manufacturing under GMP conditions while maintaining consistent sterility assurance and product release criteria across donor-derived starting materials.

Manufacturing and regulatory context: Allogeneic CAR T programs present distinct process validation challenges compared to autologous products. Donor cell sourcing, gene editing steps, and cryopreservation all introduce critical quality attributes that must be defined and controlled under 21 CFR Part 211 and ICH Q10 frameworks. As dual-targeting constructs add construct complexity, the burden on analytical development and comparability studies increases proportionally. Regulatory affairs leads monitoring this space should anticipate that CMC sections for dual-CAR products will require more extensive characterization data than single-construct predecessors.

Pipeline positioning: Allogene's active clinical programs include the ALPHA3 trial and the RESOLUTION trial, with the company also maintaining an expanded access pathway. The BCMA/CD70 dual CAR T program represents a preclinical-stage addition to this pipeline. No clinical trial initiation timeline was disclosed in the source publication.

Source: Allogene Therapeutics, published April 21, 2026. Pharma Now reports on publicly available company disclosures and does not independently verify preclinical data.